Biotech News

Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures

Pacira BioSciences (PCRX)Pacira BioSciencesCompany update

-- Select findings demonstrate that the use of EXPAREL ® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lower total healthcare costs over various follow-up periods — -- Reduced opioid use observed at 6

Related news

Pacira BioSciences

Non-Opioid Pain Management Pacira BioSciences develops and commercializes non-opioid therapies for postsurgical and musculoskeletal pain. Its portfolio combines extended-release pharmaceuticals, a cryoanalgesia device and a locally administered gene-therapy program. EXPAREL EXPAREL is a multivesicular-liposome formulation of bupivacaine...

Recent company news

Stock data

Close
24.67 USD
Market cap
875.49M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States